ultracain d-s 40 mg/0,006 mg v 1 ml raztopina za injiciranje
sanofi-aventis d.o.o. - adrenalin; artikainijev klorid - raztopina za injiciranje - adrenalin 0,005 mg / 1 ml artikainijev klorid40 mg / 1 ml; artikainijev klorid 40 mg / 1 ml - artikain, kombinacije
ultracain d-s 40 mg/0,006 mg v 1 ml raztopina za injiciranje
sanofi-aventis d.o.o. - adrenalin; artikainijev klorid - raztopina za injiciranje - adrenalin 0,005 mg / 1 ml artikainijev klorid40 mg / 1 ml; artikainijev klorid 40 mg / 1 ml - artikain, kombinacije
ultracain 2%
injekcije
ultracain 5%
injekcije
ultracain d-s forte
raztopina za injiciranje - artikain, kombinacije
ultracain d-s forte
injekcije - artikain, kombinacije
ultracain d-s injekcije 1:200.000
raztopina za injiciranje - artikain, kombinacije
tetrakain 0,5%
kapljice za oko
qdenga
takeda gmbh - dengue virus, serotype 2, expressing dengue virus, serotype 1, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 3, surface proteins, live, attenuated, dengue virus, serotype 2, expressing dengue virus, serotype 4, surface proteins, live, attenuated, dengue virus, serotype 2, live, attenuated - dengue - cepiva - qdenga is indicated for the prevention of dengue disease in individuals from 4 years of age. the use of qdenga should be in accordance with official recommendations.
dengvaxia
sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - dengue - cepiva - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 in 4. uporaba dengvaxia mora biti v skladu z uradnimi priporočili.